Nektar Therapeutics' fundamental outlook is defined by a severe revenue contraction, with TTM revenue declining 43.9% to $53.0M following the exhaustion of major collaboration milestones, leaving the company reliant on a high-cost R&D platform. The recent $903...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$1.23+37.6% vs -$1.97 | $10M-2.8% vs $10M |
Q2 2026 May 7, 2026 | -$1.82-15.0% vs -$1.58 | $11M+1.6% vs $11M |
Q2 2026 Mar 12, 2026 | -$1.78+28.1% vs -$2.47 | $22M+114.0% vs $10M |
Q4 2025 Nov 6, 2025 | -$1.85+35.1% vs -$2.85 | $12M+17.3% vs $10M |
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Profitability This table compares Evaxion A/S and Nektar
HB Wealth Management LLC purchased a new stake in Nektar Therapeutics (NASDAQ: NKTR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,315 shares of the biopharmaceutical company's stock, valued at approximately $650,000. Several other hedge funds have also bought
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease Findings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in The Lancet, a world-leading medical journal, provides the medical and scientific community with the full reporting of efficacy, safety, pharmacodynamics, pharmacokinetics, and biomarker findings from the 16-week induction period of the Phase 2b trial.
Benchmark NKTR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nektar Therapeutics (NKTR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $57.66 | $1.91B | -5.93 | -43.89% | -297.07% | -217.94% | — | |
| $112.44 | $13.34B | 43.92 | 37.55% | 24.86% | 180.63% | — | |
| $66.96 | $9.43B | -5488.52 | 23258.15% | -47.79% | -60.05% | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — | |
| $56.73 | $14.26B | 20.41 | 6.98% | 35.33% | 42.49% | — |
Nektar Therapeutics (NKTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nektar Therapeutics (NKTR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 5, 2026·SEC
May 8, 2026·SEC
Get notified when NKTR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nektar Therapeutics (NKTR) stock FAQ — growth, dividends, profitability & financials explained
Nektar Therapeutics (NKTR) reported $54.6M in revenue for fiscal year 2025. This represents a 691% increase from $6.9M in 1996.
Nektar Therapeutics (NKTR) saw revenue decline by 43.9% over the past year.
Nektar Therapeutics (NKTR) reported a net loss of $157.1M for fiscal year 2025.
Nektar Therapeutics (NKTR) has a return on equity (ROE) of -217.9%. Negative ROE indicates the company is unprofitable.
Nektar Therapeutics (NKTR) had negative free cash flow of $234.1M in fiscal year 2025, likely due to heavy capital investments.
